Tests telemedicine support to help people with pulmonary arterial hypertension take medicines
Tests remote monitoring to help adults with pulmonary arterial hypertension take oral medicine.
Plain-language title generated from the registry record
Registry title: imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
Key facts
- Where
- São Paulo, BrazilSee the site
Where in Brazil
- InCor - Universidade de São PauloSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Sao Paulo General Hospital
- Trial code
- NCT06850792
- Record updated
- 10 June 2025
- Original description
Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge. This randomized controlled study assesses whether remote monitoring can improve treatment adherence, clinical outcomes, and side effect management in PAH patients on oral therapy.Read full original descriptionShow less
imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce - A Multicenter Pre- and Post-intervention Evaluation Study
Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge. This randomized controlled study assesses whether remote monitoring can improve treatment adherence, clinical outcomes, and side effect management in PAH patients on oral therapy.
Inclusion: Adults aged ≥18 years diagnosed with pulmonary arterial hypertension (PAH) (Group 1 of the WHO classification); Stable oral PAH therapy (including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin pathway agents) for at least four weeks prior to enrollment; Ability to participate in remote teleconsultations (access to a phone or internet); Signed informed consent agreeing to study participation.
Exclusion: Concurrent participation in another interventional clinical trial that could interfere with outcomes; Severe cognitive impairment or psychiatric disorders that could affect adherence or study participation; Life expectancy <6 months due to any condition unrelated to PAH; Inability to communicate via phone or telemedicine due to technical or personal constraints; Pregnancy or breastfeeding.